Covid-19NCT04407585
Testing the Accuracy of a Digital Test to Diagnose Covid-19
An observational study of Covid-19, run by King's College London at 1 site in United Kingdom.
Trial summary
The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society. One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals, and the insufficient Covid-19 testing… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Covid-19
- What is being tested?
- Covid-19 swab PCR test
- How many people
- 1,000,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Jun 2020to 10 May 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: The study population includes individuals are UK-based primary users of the Covid Symptom Study app, who provide informed consent to participate.
Study Inclusion Criteria - app users will be eligible to join the study if they:
- Are based in the UK (are using the UK version of the Covid-19 Symptom Study app, and have listed a UK postcode)
- Are the primary app user (are reporting directly for themselves)
- Are at least 18 years of age
- Have not tested positive for a Covid-19 test before (but may have been tested)
Study Exclusion Criteria - participants are ineligible for the study if they:
- Do not meet inclusion criteria
- Do not provide informed consent to participate
Participants will be subject to further screening to identify them as eligible for swab testing during the course of the study.
Swab inclusion criteria - participants will be eligible for swab testing if they:
- Have reported in the app at least once in the previous 3 days (days -2 to 0), and at least two times in the previous 9 days (days -8 to 0). All reports must be healthy (i.e. not experiencing any symptoms).
- On the previous day (day 1), have reported that they are experiencing at least one symptom described in the app. Symptoms in the app are updated when deemed appropriate by study investigators using evidence based reports in the scientific and medical field.
- Have answered the phenotype fields required for the prediction model with physiologically plausible values.
Swab exclusion criteria - participants are ineligible for swab testing if they:
- Are asymptomatic
- Do not satisfy the inclusion criteria for testing.
Insufficient testing capacity:
If insufficient testing capacity is available for the study population as described, then recruitment will be prioritised according to:
- Firstly, most recent final healthy report before reporting symptoms
- Secondly, highest number of healthy reports during the previous 9 days before reporting symptoms
- Thirdly, randomised selection to stratify between participants of equal priority according to the first two rules above.
Excess testing capacity:
If excess testing capacity is available beyond the study population as described, then inclusion criteria will be expanded in order to adequately sample across under-represented population groups.
Specifically, on day 7 of each validation phase, investigators will assess:
- What excess testing capacity is available, if any
- Which subgroups are under-represented compared to their proportion in the UK population (as best as can be established given that some participants may not have completed some phenotype fields): (i) Age decade (ii) Sex (iii) Ethnicity (iv) BMI category
For underrepresented groups, investigators may additionally recruit participants with only one report during the previous 3 days (days -2 to 0) and no other report during the previous 9 days (days -8 to 0).
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site, 1 recruiting
- Recruiting
King's College London
London, SE1 9NH
Inbar Linenberg, MSc, +447791871699, inbar.linenberg@kcl.ac.uk
Tim Spector
About this study
Official title: Validation of Machine Learning (ML) Models as Diagnostic Tools to Predict Infection With SARS-CoV-2
The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society. One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals, and the insufficient Covid-19 testing capacity in the UK. This warrants the development of alternative diagnostic tools that reliably assess Covid-19 infection in the early stages of infection, while also being low- cost, low-burden, and easily administered to a wide proportion of the population.
This study aims to validate machine learning models as a diagnostic tool that predicts infection with SARS-CoV-2 based on app-reported symptoms and phenotypic data, against the 'gold-standard' swab PCR-test. This study will take place within the Covid Symptom Study app, the free symptom tracking mobile application launched in March 2020.
Read the detailed description
The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society (including health, education, and business and economic security). One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals. Moreover, there is insufficient Covid-19 testing capacity in the UK, and only moderate accuracy of such tests at confirming coronavirus infection. Together, these obstacles have led to countless unknown coronavirus cases going unobserved and fuelling the viral spread in the population, by compromising the stringency of self- isolation measures undertaken by infected individuals who may have otherwise curbed or prevented their transmission of the virus. The profound and widespread cost of the continuing Covid-19 progression, coinciding with the lack of testing capacity, warrants the development of alternative diagnostic tools that reliably assess Covid-19 infection in the early stages of infection, while also being low- cost, low-burden, and easily administered to a wide proportion of the population.
The free symptom-monitoring app 'Covid Symptom Study' was launched in mid-March by health technology start-up Zoe Global Ltd, and is currently being used in the UK, US and Sweden, with more than 2.7 million users in the UK alone who use the app to self-report their Covid-19 symptoms. Upon registering to use the app, users are asked to report demographic and phenotypic data such as age, sex, BMI, ethnicity, contact with infected individuals (through a healthcare professional capacity), smoking behaviour, existing health conditions, among other information. From then on, users are asked to report, on a daily basis, their presentation of symptoms attributable to Covid-19 (or lack thereof) through the use of app-administered questionnaires, thus enabling real-time tracking of disease progression across the UK. The app also allows users to report their Covid-19 test results, thus enabling the development of prediction algorithms based solely on self-reported user data to predict the presence of infection in untested users.
On behalf of Zoe Global Ltd, the UK Department of Health and Social Care with support from the UK's Chief Scientific Advisor has committed to test up to 10,000 app-users per week for infection with SARS-CoV-2 across England and Northern Ireland, for the purpose of rapidly improving the accuracy of symptom-based predictions. Similar testing allowance may follow in Scotland and Wales.
Symptomatic app-users will be asked to get tested for SARS-CoV-2 infection, using the popular swab and qRT-PCR technique, and asked to report their test results in the app, while continuing to log their symptoms.
This validation study, conducted at King's College London, aims to validate the sensitivity and specificity of machine learning models as a diagnostic tool that predicts infection with SARS-CoV-2 based on app-reported symptoms and phenotypic data, against the 'gold-standard' swab PCR-test, by utilising the Covid Symptom Study app as a research platform.
It is hypothesised that by training the symptom-based models using swab test results and through multiple model iterations following continuous data input from reporting and tested app users, predictions of infection will be made with considerable accuracy, thus enabling the Covid Symptom Study app to be used as a diagnostic tool that alleviates the strain of testing capacity in the UK while being easily accessible and posing low user burden.
Study Design:
Due to the rapidly developing and uncertain duration and intensity of the Covid-19 pandemic, the present study design is prospective and one that enables regular iteration on prediction models and continuous accumulation of validation data. The study consists of a series of phases, each lasting 14 days. Before the start of each phase (day 0), a set of machine learning models will be frozen and submitted for validation on data collected during this and subsequent phases.
Machine learning algorithms improve with increasing data. Therefore, validation phases will continue as long as tests are available and app users consent to joining the study. Due to the uncertainty around the progression of UK infection rates, the validation study will be continue whilst it is of value to public health.
A detailed statistical analysis plan is described in the document attached to this record. A record of all machine learning models used for validation will be regularly updated on GitHub (https://github.com/zoe/covid-validation-study).
- Conditions
- Covid-19
- Being tested
- Covid-19 swab PCR test
- Keywords
- Covid-19, Machine learning, Covid-19 diagnostic
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Covid-19 swab PCR testDiagnostic test
Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
| Study group | Role | What they receive |
|---|---|---|
| Covid-19 Symptom Study app-user | UK-based Covid-19 Symptom Study primary app-user completing self-reports in the app Receives: Diagnostic Test: Covid-19 swab PCR test |
What is being measured
The primary outcome is the main question the study is designed to answer.
SARS-CoV-2 infection
Likelihood of infection with Covid-19, based on app-reported symptoms
Measured: 3 days
SARS-CoV-2 infection
Active infection with Covid-19 as assessed by PCR swab test
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2020
- Study start1 Jun 2020
- Primary completion10 May 2023 (estimated)
- Study completion10 May 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid-19Studies of the same condition, open and under way.
- More trials run by King's College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Collaborators
- Zoe Global Limited, Department of Health, United Kingdom
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04407585
- Sponsor's protocol ID
- Covid-19 Validation Study
- Status last verified
- Mar 2022
- First submitted
- 27 May 2020
- Last updated
- 31 Mar 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of Machine Learning (ML) Models as Diagnostic Tools to Predict Infection With SARS-CoV-2
- ClinicalTrials.gov ID
- NCT04407585
- Acronym / sponsor ID
- Covid-19 Validation Study
- Conditions
- Covid-19
- Keywords
- Covid-19, Machine learning, Covid-19 diagnostic
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000,000 participants (estimated)
- Lead sponsor
- King's College LondonUniversity, hospital or other
- Collaborators
- Zoe Global Limited, Department of Health, United Kingdom
- Study start
- 1 Jun 2020 (actual)
- Primary completion
- 10 May 2023 (estimated)
- Study completion
- 10 May 2023 (estimated)
- First posted
- 29 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society. One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals, and the insufficient Covid-19 testing capacity in the UK. This warrants the development of alternative diagnostic tools that reliably assess Covid-19 infection in the early stages of infection, while also being low- cost, low-burden, and easily administered to a wide proportion of the population.
This study aims to validate machine learning models as a diagnostic tool that predicts infection with SARS-CoV-2 based on app-reported symptoms and phenotypic data, against the 'gold-standard' swab PCR-test. This study will take place within the Covid Symptom Study app, the free symptom tracking mobile application launched in March 2020.
Detailed description
The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society (including health, education, and business and economic security). One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals. Moreover, there is insufficient Covid-19 testing capacity in the UK, and only moderate accuracy of such tests at confirming coronavirus infection. Together, these obstacles have led to countless unknown coronavirus cases going unobserved and fuelling the viral spread in the population, by compromising the stringency of self- isolation measures undertaken by infected individuals who may have otherwise curbed or prevented their transmission of the virus. The profound and widespread cost of the continuing Covid-19 progression, coinciding with the lack of testing capacity, warrants the development of alternative diagnostic tools that reliably assess Covid-19 infection in the early stages of infection, while also being low- cost, low-burden, and easily administered to a wide proportion of the population.
The free symptom-monitoring app 'Covid Symptom Study' was launched in mid-March by health technology start-up Zoe Global Ltd, and is currently being used in the UK, US and Sweden, with more than 2.7 million users in the UK alone who use the app to self-report their Covid-19 symptoms. Upon registering to use the app, users are asked to report demographic and phenotypic data such as age, sex, BMI, ethnicity, contact with infected individuals (through a healthcare professional capacity), smoking behaviour, existing health conditions, among other information. From then on, users are asked to report, on a daily basis, their presentation of symptoms attributable to Covid-19 (or lack thereof) through the use of app-administered questionnaires, thus enabling real-time tracking of disease progression across the UK. The app also allows users to report their Covid-19 test results, thus enabling the development of prediction algorithms based solely on self-reported user data to predict the presence of infection in untested users.
On behalf of Zoe Global Ltd, the UK Department of Health and Social Care with support from the UK's Chief Scientific Advisor has committed to test up to 10,000 app-users per week for infection with SARS-CoV-2 across England and Northern Ireland, for the purpose of rapidly improving the accuracy of symptom-based predictions. Similar testing allowance may follow in Scotland and Wales.
Symptomatic app-users will be asked to get tested for SARS-CoV-2 infection, using the popular swab and qRT-PCR technique, and asked to report their test results in the app, while continuing to log their symptoms.
This validation study, conducted at King's College London, aims to validate the sensitivity and specificity of machine learning models as a diagnostic tool that predicts infection with SARS-CoV-2 based on app-reported symptoms and phenotypic data, against the 'gold-standard' swab PCR-test, by utilising the Covid Symptom Study app as a research platform.
It is hypothesised that by training the symptom-based models using swab test results and through multiple model iterations following continuous data input from reporting and tested app users, predictions of infection will be made with considerable accuracy, thus enabling the Covid Symptom Study app to be used as a diagnostic tool that alleviates the strain of testing capacity in the UK while being easily accessible and posing low user burden.
Study Design:
Due to the rapidly developing and uncertain duration and intensity of the Covid-19 pandemic, the present study design is prospective and one that enables regular iteration on prediction models and continuous accumulation of validation data. The study consists of a series of phases, each lasting 14 days. Before the start of each phase (day 0), a set of machine learning models will be frozen and submitted for validation on data collected during this and subsequent phases.
Machine learning algorithms improve with increasing data. Therefore, validation phases will continue as long as tests are available and app users consent to joining the study. Due to the uncertainty around the progression of UK infection rates, the validation study will be continue whilst it is of value to public health.
A detailed statistical analysis plan is described in the document attached to this record. A record of all machine learning models used for validation will be regularly updated on GitHub (https://github.com/zoe/covid-validation-study).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Covid-19 Symptom Study app-user | – | Diagnostic Test: Covid-19 swab PCR testUK-based Covid-19 Symptom Study primary app-user completing self-reports in the app |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The study population includes individuals are UK-based primary users of the Covid Symptom Study app, who provide informed consent to participate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Covid-19 swab PCR testParticipants satisfying machine learning test criteria will be asked to take a swab test for Covid-19. | Diagnostic test | Covid-19 Symptom Study app-user |
Primary outcome
SARS-CoV-2 infection
Time frame: 3 days
Likelihood of infection with Covid-19, based on app-reported symptoms
SARS-CoV-2 infection
Time frame: 1 day
Active infection with Covid-19 as assessed by PCR swab test
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2022.
- Individual participant dataSharing planned: No
Related trials for Covid-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid-19, run by King's College London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 31 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Inbar Linenberg, MSc (+447791871699, inbar.linenberg@kcl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SARS-CoV-2 infection (time frame: 3 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2022.